A paper from Guadamuz et al. (2024) examines trends in pharmacy closures between 2010-2021. The authors use data from the National Council for Prescription Drug Programs (to describe US retail pharmacies), National Center for Health Statistics (to […]

Drug use and homicide rates.  In 2024, ~10% of Anguilla’s GDP will come from fees for its .ai domain name. The cost of next generation sequencing for cancer patients. Chernew: Medicare at 60. Econ PhD job market is down. Egypt is malaria free!

That is a key question if long-run drug prices are going to come down for biologic products. We can decompose this question into 3 sub-questions: What share patients initiating therapy start on a biosimilar? What share of patients already using a […]

Many studies have found that patients with lower socioeconomic status (SES) have worse access to care. For instance, patients from lower SES have longer wait times (see review papers Landi et al. 2018 and Siciliani 2016). One key question is whether […]

This is a question I can’t answer with certainty. Patients often believe that since I’m part of the health-care system, I would know. But I don’t, not as a doctor — and not even when I’m a patient myself. In the United States, health […]

This is the subtitle of a study by Rebaudo et al. (2024) that aims to examine how different factors impact individual willingness to provide caregiving. The study is focused on potential caregivers in Germany. Before we get to the statistical […]

UK medicines regulator needs more resources. Big money for biosimilars. Fixing liberalism. 2024 scientific breakthroughs. The Economist: Best books of 2024.

The answer is ‘yes’, but the question is in what manner? A paper by Che et al. (2024) examines the use of real-world data (RWD) across 2016-2023 HTA assessments. Over this time period, 11% of HTA submissions included real-world data. Further, […]

That is the title of an interview with me in The Evidence Base out today with the subtitle Introducing generalized cost effectiveness analysis for a comprehensive value assessment. Below is an excerpt: What is this paper about? What is new in this […]

Meng Li (2024) has a nice summary of the generalized cost effectiveness analysis (GCEA) user guide paper (see Shafrin et al. 2024) that was published last month. The GCEA methodology encompasses 15 ‘petals’ across four domains. The uncertainty […]